Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumours (MK-7123-034)

Official Title

A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumours


The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumours: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1)
  • Dose-limiting Toxicities (DLTs) During Cycle 1
  • Adverse Events (AEs)
  • Study Treatment Discontinuations Due to an AE
Secondary Outcome:
  • Objective Response Rate (ORR) Per Modified RECIST 1.1 for Immune-based Therapeutics (iRECIST)
  • Progression-free Survival (PFS) Per RECIST 1.1
  • Overall Survival (OS)
  • Absolute Neutrophil Counts (ANC)-related AEs
  • Navarixin Area Under the Plasma Concentration-Time Curve (AUC)
  • Navarixin Maximum Plasma Concentration (Cmax)
  • Navarixin Trough Plasma Concentration (Ctrough)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society